TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Bergentoft Pharma Consulting AB
Closing information (x1000 DKK)
Closing information | 2024/12 | 2023/12 | 2022/12 |
Turnover |
1,333
|
1,373 | |
Financial expenses |
5
|
0 | |
Earnings before taxes |
1,165
|
846 | |
EBITDA |
1,154
|
846 | |
Total assets |
2,673
|
1,963 | |
Current assets |
2,031
|
1,295 | |
Current liabilities |
420
|
512 | |
Equity capital |
2,084
|
1,348 | |
- share capital |
34
|
33 | |
Employees (average) |
1
|
2
|
1 |
Financial ratios
Fiscal year | 2024/12 | 2023/12 | 2022/12 |
Solvency |
78.0%
|
68.7% | |
Turnover per employee |
666
|
1,373 | |
Profit as a percentage of turnover |
87.4%
|
61.6% | |
Return on assets (ROA) |
43.8%
|
43.1% | |
Current ratio |
483.6%
|
252.9% | |
Return on equity (ROE) |
55.9%
|
62.8% | |
Change turnover |
-47
|
587 | |
Change turnover % |
-100%
|
-3%
|
75% |
Chg. No. of employees |
-1
|
1
|
0 |
Chg. No. of employees % |
-50%
|
100%
|
0% |
Total value of public sale
Fiscal year | 2024/12 | 2023/12 | 2022/12 |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.